Equillium (STU:0FY) Total Liabilities : €20.70 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Equillium Total Liabilities?

Equillium's Total Liabilities for the quarter that ended in Mar. 2024 was €20.70 Mil.

Equillium's quarterly Total Liabilities declined from Sep. 2023 (€29.16 Mil) to Dec. 2023 (€25.64 Mil) and declined from Dec. 2023 (€25.64 Mil) to Mar. 2024 (€20.70 Mil).

Equillium's annual Total Liabilities increased from Dec. 2021 (€16.73 Mil) to Dec. 2022 (€43.88 Mil) but then declined from Dec. 2022 (€43.88 Mil) to Dec. 2023 (€25.64 Mil).

Equillium Total Liabilities Historical Data

The historical data trend for Equillium's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Equillium Total Liabilities Chart

Equillium Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

12.32

12.80

16.73

43.88

25.64

Equillium Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															39.72	29.34	29.16	25.64	20.70

Equillium Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Equillium's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	25.284	+	(0.352	+	0.0010000000000016
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	25.64

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	46.336	-	20.699
	=	25.64

Equillium's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	20.431	+	(0.271	+	0.00099999999999845
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	20.70

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	40.109	-	19.406
	=	20.70

Equillium Total Liabilities Related Terms

Thank you for viewing the detailed overview of Equillium's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Equillium (STU:0FY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Equillium Inc (STU:0FY) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

EQ:USA

Address

2223 Avenida De La Playa, Suite 105, La Jolla, CA, USA, 92037

Website

https://www.equilliumbio.com

Equillium Inc is a biotechnology developing therapies to treat autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph 2 ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.

Equillium (STU:0FY) Headlines

No Headlines